Differential expression of lncRNA in patients with coronary artery disease plus clopidogrel resistance.
10.11817/j.issn.1672-7347.2019.01.002
- Author:
Wenjian XIE
1
;
Beibei HUANG
2
;
Qian YIN
2
;
Shaoliang CHEN
1
Author Information
1. Department of Cardiology, Nanjing Hospital Affiliated to Nanjing Medical University, Nanjing 210006, China.
2. General Clinical Research Center, Nanjing Hospital Affiliated to Nanjing Medical University, Nanjing 210006, China.
- Publication Type:Journal Article
- MeSH:
Clopidogrel;
Coronary Artery Disease;
genetics;
Humans;
Percutaneous Coronary Intervention;
Platelet Aggregation;
Platelet Aggregation Inhibitors;
RNA, Long Noncoding
- From:
Journal of Central South University(Medical Sciences)
2019;44(1):9-13
- CountryChina
- Language:Chinese
-
Abstract:
To explore differential expression of long non-coding RNA (lncRNA) in patients with coronary artery disease plus clopidogrel resistance.
Methods: Patients underwent percutaneous coronary intervention (PCI) and treated with clopidogrel were recruited, and their clinical data and blood samples were collected. Patients were divided into a clopidogrel sensitive group and a clopidogrel resistance group according to platelet aggregation rate. lncRNA microarray and real-time RT-PCR were performed in 5 and 34 patients in each group, respectively.
Results: lncRNA microarray showed that 11 lncRNAs in peripheral leukocytes were up-regulated and 8 lncRNAs were down-regulated in clopidogrel resistant group. Real-time PCR indicated that two lncRNAs (NONHSAT083775.2 and NONHSAT107804.2) in leukocytes were up-regulated and one lncRNA (NONHSAT133455.2) was down-regulated in the clopidogrel resistant group compared with the clopidogrel sensitive group, consistent with the results of lncRNA microarray.
Conclusion: Clopidogrel resistance is associated with the up-regulation of lncRNA NONHSAT083775.2 and NONHSAT107804.2 and the down-regulation of NONHSAT133455.2.
